探讨低分子肝素治疗慢性阻塞性肺疾病急性加重期的临床治疗效果

Discussion on clinical treatment effect of low molecular weight heparin in the treatment of acute exacerbation of chronic obstructive pulmonary disease

目的对慢性阻塞性肺疾病急性加重期患者采取低分子肝素进行治疗,分析其临床疗效。方法 86例慢性阻塞性肺疾病急性加重期患者,按照随机原则分为对照组与研究组,每组43例。对照组进行常规治疗,研究组在常规治疗的基础上加以低分子肝素进行治疗,比较分析两组疗效。结果治疗前,研究组全血粘度、血浆粘度、纤维蛋白原水平分别为(5.12±0.23)mPa·s、(1.65±0.18)mPa·s、(5.89±0.89)g/L,对照组全血粘度、血浆粘度、纤维蛋白原水平分别为(5.15±0.23)mP·s、(1.63±0.14)mPa·s、 a(5.79±0.64)g/L,比较差异无统计学意义(P>0.05)。治疗后,研究组全血粘度、血浆粘度、纤维蛋白原水平分别为(3.92±0.16)mPa·s、(0.92±0.18)mPa·s、(3.85±0.23)g/L,对照组全血粘度、血浆粘度、纤维蛋白原水平分别为(4.25±0.27)mPa·s、(1.15±0.24)mPa·s、(4.34±0.21)g/L,研究组全血粘度、血浆粘度、纤维蛋白原水平均优于对照组,差异具有统计学意义(t=6.895、5.027、10.317,P<0.05)。研究组总有效率97.7%高于对照组的83.7%,差异具有统计学意义(P<0.05)。结论针对患有慢性阻塞性肺疾病急性加重期患者开展治疗时选用低分子肝素,能够取得良好的整体疗效,值得将在临床推广。

Objective To analyze the clinical efficacy of low molecular weight heparin in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods A total of 86 patients with acute exacerbation of chronic obstructive pulmonary disease were randomly divided into control group and research group, with 43 cases in each group. The control group received conventional therapy, and the research group received low molecular weight heparin on the basis of conventional therapy. The efficacy in two groups was compared and analyzed. Results Before treatment, the research group had whole blood viscosity, plasma viscosity and fibrinogen level respectively as（5.12±0.23） mPa·s,（1.65±0.18）mPa·s and（5.89±0.89） g/L, which were respectively（5.15±0.23） mPa·s,（1.63±0.14） mPa·s and（5.79±0.64） g/L in the control group, and their difference was statistically significant（P〉0.05）. After treatment, the research group had whole blood viscosity, plasma viscosity and fibrinogen level respectively as（3.92±0.16） m Pa·s,（0.92±0.18） mPa·s and（3.85±0.23） g/L, which were respectively as（4.25±0.27） mPa·s,（1.15±0.24） mPa·s and（4.34±0.21） g/L in the control group. The research group had better whole blood viscosity, plasma viscosity and fibrinogen level than the control group, and their difference was statistically significant（t=6.895, 5.027, 10.317, P〈0.05）. The research group had higher total effective rate as 97.7% than 83.7% in the control group, and the difference was statistically significant（P〈0.05）. Conclusion For patients with acute exacerbation of chronic obstructive pulmonary disease, application of low molecular weight heparin can achieve good overall efficacy, and this method is worthy of promotion.